CT 303
Alternative Names: CT-303Latest Information Update: 12 Apr 2023
At a glance
- Originator GC Cell
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Plaque psoriasis
- Preclinical Adult respiratory distress syndrome
Most Recent Events
- 04 Apr 2023 GC Cell withdrawn a phase I trial in adult respiratory distress syndrome in South Korea due to difficulties in recruiting subjects (NCT05238532)
- 10 Dec 2021 Phase-I clinical trials in Plaque psoriasis in South Korea (Parenteral)
- 20 Oct 2021 The Ministry of Food and Drug Safety approves IND application for CT 303 in Adult respiratory distress syndrome in South Korea